Cyclosporine C2 Levels Have Impact on Incidence of Rejection in De Novo Lung but Not Heart Transplant Recipients: The NOCTURNE Study

Journal of Heart and Lung Transplantation

Volumn 28, Issue 9, 2009, Pages 919-926

  Iversen, Martin ^a   Nilsson, Folke ^b   Sipponen, Jorma ^c   Eiskjaer, Hans ^d   Mared, Lena ^e   Bergan, Stein ^f   Nyström, Ulla ^b   Fagertun, Hans E ^f   Solbu, Dag ^f   Simonsen, Svein ^f  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; EMPHYSEMA; FEMALE; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; BLOOD PRESSURE; CARDIOMYOPATHIES; CORONARY ARTERY DISEASE; CREATININE; CYCLOSPORINE; CYSTIC FIBROSIS; EMPHYSEMA; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 68949215040     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.022     Document Type: Article

References (30)

1. Barr W.H. Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. Transplant Proc 31 suppl (1999) 25S-30S
2. Lemaire M., Fahr A., and Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplant Proc 22 (1990) 1110-1112
3. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 58 (1994) 658-663
4. Levy G.A. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 15 (2001) 279-290
5. International Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2 (2002) 148-156
6. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72 (2001) 1024-1032
7. Cantarovich M., Barkun J.S., Tchervenkov J.I., et al. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66 (1998) 1621-1627
8. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12 (1998) 243-249
9. Belitsky P., Dunn S., Johnston A., et al. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 39 (2000) 117-125
10. Johnston A., David O.J., and Cooney G.F. Pharmacokinetic validation of neoral absorption profiling. Transplant Proc 32 suppl (2000) 53S-56
11. Cantarovich M., Barkun J., Besner J.G., et al. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Transplant Proc 30 (1998) 1462-1463
12. Jaksch P., Kocher A., Neuhauser P., et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 24 (2005) 1076-1080
13. Pescovitz M.D., and Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 16 (2002) 378-382
14. Knight S.R., and Morris P.J. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83 (2007) 1525-1535
15. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 36 suppl (2004) 420S-425
16. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant 9 (1990) 587-593
17. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. J Heart Lung Transplant 15 (1996) 1-15
18. Parekh K., Trulock E., and Patterson G.A. Use of cyclosporine in lung transplantation. Transplant Proc 36 suppl (2004) 318S-322
19. Chou N.K., Chen R.J., Ko W.J., et al. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan. Transplant Proc 36 (2004) 2393-2395
20. Cantarovich M., Giannetti N., and Cecere R. Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 18 (2004) 148-151
21. Akhlaghi F., Gonzalez L., and Trull A.K. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 24 (2005) 2120-2128
22. Glanville A.R., Aboyoun C.L., Morton J.M., et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 25 (2006) 928-934
23. Morton J.M., Aboyoun C.L., Malouf M.A., et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 23 (2004) 1035-1039
24. Hangler H.B., Ruttmann E., Geltner C., et al. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation. Clin Transplant 22 (2008) 35-40
25. Schubert S., Abdul-Khaliq H., Lehmkuhl H.B., et al. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant 25 (2006) 619-625
26. Barnard J.B., Thekkudan J., Richardson S., et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 25 (2006) 564-568
27. Puehler T., Goepel L., Tschirschnitz M., et al. C2 therapeutic drug monitoring of cyclosporine is a safe and feasible method in de novo heart transplant patients. Transplant Proc 39 (2007) 3329-3333
28. Hornum M., Burton C.M., Iversen M., et al. Decline in 51Cr-labelled EDTA measured glomerular filtration rate following lung transplantation. Nephrol Dial Transplant 22 (2007) 3616-3622
29. Al Aly Z., Abbas S., Moore E., et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 19 (2005) 683-689
30. Hornum M., Iversen M., Steffensen I., et al. Rapid decline in 51-Cr EDTA measured renal function during the first weeks following lung transplantation. Am J Transplant 9 (2009) 1420-1426